A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.
Also called NCT03897868
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 248 participants
- Registry
-
NCT03897868
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03897868. Randomized; double masking; primary purpose treatment. Start 2019-03-21 (actual); primary completion 2020-02-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
- Acronym
- HM_APOLLO
- Condition
- Hypertension
- Intervention (Drug)
- HCP1803
- Intervention (Drug)
- Amlodipine
- Intervention (Drug)
- Losartan
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct03897868- Content hash
1436808dd24f7f10a2ad943f531d272211908bad99a0c4b2a11c9c73d97d67a1